Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief
Stocks in this Quantisnow insightHealth Care
Historical context for ASBP
Across the 8 sessions after earlier ASBP headlines, the stock closed higher 6 times and lower 2 times, with a median move of 8.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ASBP | SPY |
|---|---|---|---|
| Jan 14, 2026 | Aspire Biopharma Announces Reverse Stock Split | -26.4% | -0.5% |
| Jan 7, 2026 | Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA) | +19.6% | -0.3% |
| Dec 18, 2025 | Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine | +4.6% | +0.8% |
| Dec 15, 2025 | Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements | +13.1% | -0.2% |
| Dec 4, 2025 | Aspire Biopharma Provides Q3 2025 Business Update | +3.3% | +0.1% |
| Dec 2, 2025 | Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) | +1.1% | +0.2% |
Keep researching ASBP
Quantisnow market dataNASDAQ
ASBP
Aspire-Lakewood Holdings Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2022
Get push alerts for ASBP
Full ASBP profile on Quantisnow Follow ASBP and get a push notification the moment its next story breaks.